Premium
Pru p 3‐Glycodendropeptides Based on Mannoses Promote Changes in the Immunological Properties of Dendritic and T‐Cells from LTP‐Allergic Patients
Author(s) -
Palomares Francisca,
RamosSoriano Javier,
Gomez Francisca,
Mascaraque Ainhoa,
Bogas Gador,
Perkins James Richard,
Gonzalez Miguel,
Torres Maria Jose,
DiazPerales Araceli,
Rojo Javier,
Mayorga Cristobalina
Publication year - 2019
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.201900553
Subject(s) - immune system , immunology , dendritic cell , mannose receptor , allergic response , medicine , chemistry , immunoglobulin e , macrophage , antibody , biochemistry , in vitro
Scope Glycodendropeptides (GDPs) functionalized with mannose can enhance allergen interaction with dendritic cells (DCs) via C‐type lectin receptors (CLRs), modulating the immune response. They can present multiple peptides and have potential applications for diagnosis and treatment of food allergy (FA). The immune response induced by GDPs with mannose and Pru p 3 peptides (mono/tetravalent) with ester (D 1 ManPrup3/D 4 ManPrup3) or ether linkers (D 1 Man ‐O‐ Prup3/D 4 Man ‐O‐ Prup3) in lipid‐transfer‐protein‐allergic patients and tolerant controls is analyzed. Methods and results The immunological response induced by GDPs is studied by assessing monocyte‐derived‐DC maturation, lymphocyte proliferation, cytokine production, and basophil response by flow cytometry. D n ManPrup3 was recognized by DCs via CLRs inducing DC maturation in all subjects. However, CCR7 expression is significantly upregulated in allergic patients compared to tolerant controls. These changes correlate with lymphocyte proliferation and specific production of Th2/Th1 cytokines in allergic patients. Moreover, D 1 ManPrup3 does not induce basophil activation. Conclusion D n ManPrup3 induces changes in DC maturation and lymphocyte proliferation, indicating specific recognition via CLRs. Prup3‐GDPs are recognized by immune cells, inducing a specific immune response and modulating the immunological response in FA patients. The specific geometry of D 1 ManPrup3 in particular makes it a potential candidate for specific immunotherapy development.